Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mahamaya Lifesciences's earnings per share without non-recurring items for the
six
months ended in Mar. 2026 was ₹3.72.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3.72.
During the past 12 months, Mahamaya Lifesciences's average earnings per share (NRI) Growth Rate was 52.20% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 73.50% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Mahamaya Lifesciences's EPS without NRI or its related term are showing as below:
BOM:544611'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 67.5 Med: 70.5 Max: 73.5
Current: 73.5
During the past 5 years, Mahamaya Lifesciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 73.50% per year. The lowest was 67.50% per year. And the median was 70.50% per year.
BOM:544611's 3-Year EPS without NRI Growth Rate is ranked better than 96.73% of 214
companies
in the Agriculture industry
Industry Median: -3.75
vs BOM:544611: 73.50
Mahamaya Lifesciences (BOM:544611) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Mahamaya Lifesciences EPS without NRI Related Terms
Mahamaya Lifesciences EPS without NRI Historical Data
* Premium members only.
The historical data trend for Mahamaya Lifesciences's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544611 vs CTVA, CF, MOS: EPS without NRI Comparison
For the Agricultural Inputs subindustry, Mahamaya Lifesciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mahamaya Lifesciences PE Ratio without NRI vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Mahamaya Lifesciences's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Mahamaya Lifesciences's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹3.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mahamaya Lifesciences (BOM:544611) has a EPS without NRI of ₹3.72 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Mahamaya Lifesciences and its competitors. According to the industry distribution chart, Mahamaya Lifesciences ranks #7 out of 214 companies in the Agriculture industry, placing it in the top 3.3%.
Is Mahamaya Lifesciences' EPS without NRI too high?
Mahamaya Lifesciences' current EPS without NRI is ₹3.72. Based on the distribution chart, Mahamaya Lifesciences ranks #7 out of 214 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' EPS without NRI compare to CTVA and CF?
According to the Agriculture industry distribution chart, Mahamaya Lifesciences ranks #7 out of 214 companies for EPS without NRI. This places Mahamaya Lifesciences in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for an Agriculture company?
A good EPS without NRI depends on the Agriculture industry context. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Mahamaya Lifesciences and its competitors. Mahamaya Lifesciences's current EPS without NRI is ₹3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current EPS without NRI of ₹3.72. The current EPS without NRI is ₹3.72. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current EPS without NRI is ₹3.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score
Get the complete analysis for BOM:544611
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544611 has been successfully added to your 
